Carver and co-workers showed that combination therapy targeting both AR and PI3K-AKT-mTOR signaling caused near complete regression in a PTEN-deficient mouse model with PCa.13 Against both signaling pathways a number of clinically approved drugs are available.14 Schwartz and colleagues took advantage of these pharmacological advances and chose drug combinations against AR and multiple PI3K isoforms and suggested that the largest tumor mass reduction was achieved using a triple drug combination.15 The gene discussed is AR; the disease is neoplasm.